Keywords: bayer/j, xarelto, drive, anticoagulant, market, entries, oral

Bayer/J&J's Xarelto will drive anticoagulant market

Article | 22 October 2007

Print This

Market entries of oral agents that do not require dose- adjustment or monitoring, particularly the entry of Bayer/Johnson & Johnson's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in